Cobra & Alligator Form Alliance for Monoclonal Antibody

Cobra Biologics and Alligator Bioscience have signed a manufacturing services and supply agreement for the production of monoclonal antibody drug product.

UK-based Cobra Biologics and Swedish drug discovery and development company Alligator Bioscience have entered into a manufacturing services and supply agreement for the production of monoclonal antibody drug product for preclinical and Phase I and II trials.
 
Cobra will provide cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP supplies, as well as stability studies and QP release for clinical trials.
 
Alligator will utilize the maxXpress service, which combines the UCOE protein expression technology with Cobra’s cell line development team and the Cello robotic clone selection system, designed to enable rapid clone selection and production of the monoclonal antibody.